Xtant Medical Holdings Inc (XTNT)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
$0.30+1.35%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · XTNT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.2% |
| Our one-year growth estimate | diamond | 0.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 86.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 43 industry peers
XTNT — earnings miss
Dated 2026-08-11
of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. To supplement its…
Why it matters: Q2 revenue was $23.0 million, and the company cut its 2026 revenue range. Q3 results test whether sales stay on that path.
Watch forQ3 revenue is at least $24.8 million, the quarterly average needed to reach $99 million for 2026 after Q1 and Q2.
Also watch forQ3 revenue is below $24.8 million, putting the low end of the $99 million full-year range further out of reach.
Why it matters: Cash fell to $9.9 million, and unused credit fell to $0.7 million. The next report can show whether the company keeps enough funds to run its business.
Worry ifAt Q3 end, cash is below $9.9 million and unused credit is below $0.7 million.
Less concerning ifAt Q3 end, cash is at least $9.9 million and unused credit is at least $0.7 million.
Why it matters: Xtant raised its revenue range after adding HEMOBLAST, then cut it after weak biologics sales. Sales data can show whether the deal adds revenue.
Supportive ifThe next report names HEMOBLAST sales and shows that quarterly revenue from the product is rising.
Worry ifThe next report says HEMOBLAST sales are flat or down, or that the distribution deal has ended.
Why it matters: Q2 gross margin fell to 57.9%. Lower plant output and inventory charges added to the loss of high-margin license revenue.
Supportive ifQ3 gross margin tops 57.9%, with lower charges for excess or outdated inventory.
Worry ifQ3 gross margin stays at or below 57.9%, or inventory charges rise from Q2.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$181 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $544 loss on $10,000 · 5.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,604 loss on $10,000 · 66.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.